The first external validation of the Dallas steatosis index in biopsy-proven Non-alcoholic fatty liver Disease: A multicenter study-Reference-Cited by-同舟云学术

The first external validation of the Dallas steatosis index in biopsy-proven Non-alcoholic fatty liver Disease: A multicenter study

Published:2023-09 Issue: Volume:203 Page:110870
ISSN:0168-8227
Container-title:Diabetes Research and Clinical Practice
language:en
Short-container-title:Diabetes Research and Clinical Practice

Author:

Kouvari Matina,Mylonakis Sophia C.,Katsarou Angeliki,Valenzuela-Vallejo Laura^ORCID,Guatibonza-Garcia Valentina,Kokkorakis Michail^ORCID,Verrastro Ornella,Angelini Giulia,Markakis Georgios,Eslam Mohammed,George Jacob,Papatheodoridis Georgios,Mingrone Geltrude,Mantzoros Christos S.

Funder

Massachusetts Life Sciences Center

Boehringer Ingelheim

Merck Sharp and Dohme

Publisher

Elsevier BV

Subject

Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference44 articles.

1. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review;Younossi;Hepatol Baltim Md,2023

2. Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach;Le;Clin Mol Hepatol,2022

3. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes;Godoy-Matos;Diabetol Metab Syndr,2020

4. Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) Registry;Younossi;Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc,2022

5. Mediterranean diet is inversely associated with steatosis and fibrosis and decreases ten-year diabetes and cardiovascular risk in NAFLD subjects: Results from the ATTICA prospective cohort study;Kouvari;Clin Nutr Edinb Scotl,2021

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Accuracy of Noninvasive Indices for Diagnosing Hepatic Steatosis Compared to Controlled Attenuated Parameter (CAP) in a Lebanese Cohort.;2024-07-15

2. Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges;Metabolism;2024-05

3. Steatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies;Pharmacological Reviews;2024-01-30

4. Thyroid function, adipokines and mitokines in metabolic dysfunction‐associated steatohepatitis: A multi‐centre biopsy‐based observational study;Liver International;2024-01-23

5. Questionnaire-Based Prediction of Incident Coronary Artery Disease: Developing and Validating Machine Learning Models for Multiple Populations;2024